ArticleFrontiers in oncology2020

PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer.

Alexandre Bertucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.